The Effect of Irrisept for Irrigation of Skin and Soft Tissue Infections (Irrisept USF Study)
Evaluation of a Novel Solution, IrriSept, a New Delivery System, Containing a Long-acting Antimicrobial Agent for Irrigation of Skin and Soft Tissue Infections, in the Form of an Abscess in the Emergency Department: a Pilot Study
Sponsor: Irrimax Corporation
Terminated
Suboptimal Recruitment
Other terminated trials from Irrimax Corporation
- Surgical Site Infection · Phase NA · Mar 2017
- Abscess · Phase NA · Aug 2012
- Abscess · Phase NA · Nov 2011
More terminations from Irrimax Corporation
Other Abscess trials with similar outcome
This NA trial investigates Abscess and Skin and Soft Tissue Infections and is currently terminated or withdrawn. Irrimax Corporation leads this study, which shows 9 recorded versions since 2010 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
-
Sep 2021 — Dec 2022 [monthly]
Terminated NA
Phase: PHASE2 → NA
▶ Show 4 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Irrimax Corporation
For direct contact, visit the study record on ClinicalTrials.gov .